Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a biopharmaceutical company headquartered in Chicago, Illinois, with a commercial portfolio and pipeline focused on endocrine and neurological conditions. News about Xeris frequently centers on the performance of its three marketed products—Recorlev, Gvoke, and Keveyis—as well as updates on its lead pipeline candidate, XP-8121, and its proprietary XeriSol and XeriJect formulation platforms.
Investors following XERS news can expect regular coverage of quarterly and full-year financial results, including product-level revenue for Recorlev, Gvoke, and Keveyis, trends in patient demand, and commentary on profitability metrics such as Adjusted EBITDA. The company’s press releases and accompanying Form 8-K filings provide detailed breakdowns of revenue, costs, and operating performance, along with management’s discussion of strategic priorities.
Xeris news flow also includes announcements related to intellectual property, such as Orange Book listings and patent notices for Recorlev and XP-8121, as well as partnership updates like the agreement with American Regent for the commercialization of Gvoke VialDx in the United States. Additional items may cover analyst and investor events, revenue guidance updates, and long-term outlooks that management shares with the market.
For those tracking developments in Xeris’ pipeline, news items highlight regulatory milestones, patent allowances, and R&D investment in XP-8121 and other early-stage programs using XeriSol and XeriJect. By monitoring this news page, readers can review a chronological record of Xeris’ operational, financial, and strategic announcements as they are released.
Xeris Biopharma Holdings (NASDAQ: XERS) announced a private placement agreement with Armistice Capital, expected to close on January 3, 2022, for gross proceeds of approximately $30.0 million. The deal involves issuing 10,238,908 shares of common stock at $2.93 each and warrants to purchase an additional 5,119,454 shares at $3.223. Proceeds will be allocated to operational support, product marketing, clinical trials, and general corporate purposes. The shares will not be registered under the Securities Act upon issuance and will require a resale registration statement.
Xeris Biopharma announced FDA approval for Recorlev (levoketoconazole), a treatment for Cushing's syndrome in adults where surgery isn't an option. The decision follows the acquisition of Strongbridge Biopharma on October 5, 2021. Safety and efficacy were supported by positive results from two pivotal Phase 3 studies (SONICS and LOGICS) involving 166 patients. A commercial launch is planned for Q1 2022, positioning Xeris to meet the treatment needs of this patient population.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announced the UK launch of Ogluo® (glucagon injection) through its commercialization partner, Tetris Pharma, for treating severe hypoglycemia in diabetes patients aged 2 and over. This follows a licensing deal in July for Ogluo's commercialization in the UK and EU. Xeris estimates around 5 million people in the UK are at risk of severe hypoglycemia, with only 10-20% currently prescribed glucagon. The launch aims to increase accessibility and provide a ready-to-use solution for emergencies.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) reported strong third-quarter performance with pro forma net sales of $22.5 million, driven by Gvoke and Keveyis, expected to reach $76-$80 million for 2021. The acquisition of Strongbridge Biopharma was finalized on October 5, 2021, with integration completed and $50 million in synergies anticipated. The company boasts a robust cash position of approximately $100 million at year-end, along with a 12-month extension on its debt facility, pushing principal repayments to 2023.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will report its third quarter 2021 financial results on November 10, 2021, before the U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company develops therapies in endocrinology, neurology, and gastroenterology, with products like Gvoke® and Keveyis®. Interested parties can pre-register for the call via the provided link, and a replay will be available until November 24, 2021.
Xeris Biopharma Holdings (Nasdaq: XERS) announced a collaboration with Merck to explore the licensing of its XeriJect™ technology for ultra-high concentration monoclonal antibodies. Although financial terms were not disclosed, this collaboration aims to improve the delivery of large molecules and is part of Xeris' ongoing partnerships with major pharmaceutical companies. Xeris highlighted the importance of its product portfolio, including commercialized therapies Gvoke® and Keveyis®, and a robust pipeline, indicating a solid financial position bolstered by a $50 million synergy from the Strongbridge acquisition.
Xeris Pharmaceuticals has successfully completed its acquisition of Strongbridge Biopharma, creating Xeris Biopharma Holdings. The deal values Strongbridge at approximately
Xeris Pharmaceuticals (NASDAQ: XERS) announced the grant of restricted stock units totaling 28,750 shares to 20 new employees as part of its Inducement Equity Plan, effective October 1, 2021. This plan incentivizes new hires not previously employed by Xeris, adhering to NASDAQ rules. The stock options will vest over four years, contingent on continued employment. Xeris is focused on innovative drug formulations, including its first commercial product, Gvoke, utilizing room-temperature stable formulations to enhance patient and healthcare provider experiences.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced that CEO Paul R. Edick will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 8:15 a.m. ET. The presentation can be accessed via the company's website. Xeris focuses on developing ready-to-use injectable drug formulations using its proprietary XeriSol™ and XeriJect™ technologies, which aim to simplify therapy administration and improve patient experiences. Xeris is headquartered in Chicago, IL.
Xeris Pharmaceuticals (XERS) has received overwhelming approval from its stockholders for the acquisition of Strongbridge Biopharma (SBBP). At a special meeting on September 14, 2021, approximately 97% of shares voted in favor, equating to about 59% of Xeris' total outstanding shares. The acquisition, set to close in early October 2021, will merge the businesses under Xeris Biopharma Holdings, Inc. This strategic move aims to strengthen Xeris' position in endocrinology and neurology, leveraging a differentiated technology platform to address unmet patient needs.
FAQ
What is the current stock price of Xeris Biopharma Holdings (XERS)?
What is the market cap of Xeris Biopharma Holdings (XERS)?
